These results are consistent with findings from a Phase 1b clinical trial that showed the gedatolisib/fulvestrant/palbociclib triplet was similarly effective in ABC patients regardless of PIK3CA mutations, both in CDK4/6 inhibitor-naïve and CDK4/6 inhibitor-pretreated patients [44]. Here, CDK4 is linked to aneurysmal bone cyst.